Prof. Dr. Murat ALBAYRAK

1. Outcomes of Brentuximab Vedotin Monotherapy in Refractory/Relapsed Classical Hodgkin’s Lymphoma: A Multi-Center Retrospective Study on Survival and Safety

Bakirtas M., Hindilerden I. Y., Ulu B. U., Ekinci O., Dogu M. H., Aydogdu I., et al.

Indian Journal of Hematology and Blood Transfusion , cilt.42, sa.3, ss.781-791, 2026 (SCI-Expanded, Scopus)

2. Prognostic Differences Between P190 and P210 BCR::ABL1 in Patients with Philadelphia-Positive B-cell Acute Lymphoblastic Leukemia

Pepeler M., Oztürk F., Okumus N., Dal M., Yaman S., Can F., et al.

Indian Journal of Hematology and Blood Transfusion , cilt.42, sa.1, ss.110-119, 2026 (SCI-Expanded, Scopus)

3. Novel mutated Dubin–Johnson syndrome diagnosed during acute promyelocytic leukemia treatment

AFACAN ÖZTÜRK H. B., ALBAYRAK M., Reis Aras M., Yılmaz F., Düzkale N.

Memo - Magazine of European Medical Oncology , cilt.18, sa.2, ss.125-128, 2025 (ESCI, Scopus)

4. Prognostic Impact of Bone Marrow Fibrosis and Effects of Tyrosine Kinase Inhibitors on Bone Marrow Fibrosis in Chronic Myeloid Leukemia

Pepeler M. S., Tıglıoglu M., DAĞDAŞ S., Ozhamamcıoglu E., Han U., Albayrak A., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.24, sa.4, 2024 (SCI-Expanded, Scopus)

5. Mean platelet volume and platelet distribution width in the prediction of treatment response in immune thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a multicenter study

Sayın S., YILDIRIM M., GÜNEŞ A. K., Aras M. R., Yılmaz E. Ş., ALBAYRAK M., et al.

Gulhane Medical Journal , cilt.66, sa.1, ss.43-48, 2024 (Scopus, TRDizin)

6. Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis Proteazom İnhibitörleri ve İmmünomodülatör Ajanlar Çağında Primer Plazma Hücreli Lösemili Hastaların Sağkalım Sonuçları: Gerçek Yaşam Verilerinden Çok Merkezli Bir Analiz

ATAŞ Ü., SALİM O., ILTAR U., YÜCEL O. K., Eroğlu A. H. K., Aslan V., et al.

Turkish Journal of Hematology , cilt.41, sa.4, ss.225-235, 2024 (SCI-Expanded, Scopus, TRDizin)

7. The Prognostic Impact of Comorbidity, Nutritional and Performance Status on Patients with Diffuse Large B Cell Lymphoma

Saǧlam B., ALBAYRAK M., Yildiz A., Tiǧlioǧlu P., Tiǧlioǧlu M., Aras M., et al.

Nigerian Journal of Clinical Practice , cilt.26, sa.10, ss.1512-1518, 2023 (SCI-Expanded, Scopus)

8. The Utility of CONUT Score in Indolent Lymphoma Patients

Tiǧlioǧlu M., Öztürk H., Yildiz A., Tiǧlioǧlu P., Yilmaz F., Aras M., et al.

Nigerian Journal of Clinical Practice , cilt.26, sa.9, ss.1290-1296, 2023 (SCI-Expanded, Scopus)

9. Evaluation of Second Primary Cancer Risk Among Chronic Lymphocytic Leukemia Patients: Multicenter Study

Sayin S., Kiliacslan E., YILDIRIM M., AFACAN ÖZTÜRK H. B., Safak Yilmaz E., ALBAYRAK M., et al.

Asian Pacific journal of cancer prevention : APJCP , cilt.24, sa.6, ss.1971-1977, 2023 (Scopus)

10. Comparison of maintenance regimens in Acute Promyelocytic Leukemia patients

Kilic Gunes E., ÖZKURT Z. N., Yildiz S., Ozet G., CERAN F., ALBAYRAK M., et al.

Leukemia Research , cilt.128, 2023 (SCI-Expanded, Scopus)

11. Treatment options in primary mediastinal B cell lymphoma patients, retrospective multicentric analysis; a Turkish oncology group study

Acar R., PAYDAŞ S., YILDIRIM M., Kiliçarslan E., ŞAHİN U., DOĞAN A. A., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.8, 2023 (SCI-Expanded, Scopus)

12. International Forum: The Turkish perspective on apheresis activity: The Turkish apheresis registry report

Özatlı D., Giden A. O., ERKURT M. A., KORKMAZ S., BAŞCI S., Ulas T., et al.

Transfusion and Apheresis Science , cilt.62, sa.2, 2023 (SCI-Expanded, Scopus)

13. The Charlson Comorbidity Index Predicts Poor Prognosis in Elderly AML Patients

Tiglioglu M., ALBAYRAK M., Tiglioglu P., Yildiz A., Dogan S., AFACAN ÖZTÜRK H. B., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.33, sa.1, ss.1-7, 2023 (SCI-Expanded, Scopus, TRDizin)

14. Serum thrombin-activatable fibrinolysis inhibitor levels and its relation with pathogenesis and bleeding and prognosis in patients with Crimean Congo hemorrhagic fever

Altin N., Altay F. A., ALBAYRAK M., Sahingoz S. O., ŞENCAN İ.

Journal of Medical Virology , cilt.95, sa.1, 2023 (SCI-Expanded, Scopus)

15. Co-occurence of follicular lymphoma and Langerhans cell histiocytosis with primary parotid gland involvement: a case report

Albayrak A., Yıldız A., ALBAYRAK M., Özhamam E. U., Maral S.

Hematology, Transfusion and Cell Therapy , cilt.45, sa.1, ss.131-133, 2023 (ESCI, Scopus)

16. Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study Kronik Faz Kronik Myeloid Lösemi Hastalarında İmatinib Tedavisinin Kesilmesinin Uzun Dönem Sonuçları: Ulusal Çok Merkezli Prospektif Bir Çalışma

SAVAŞ E. M., YILMAZ S., Dikyar A. A. B., ÖZKURT Z. N., ÖÇAL R., Can F., et al.

Turkish Journal of Hematology , cilt.40, sa.4, ss.236-241, 2023 (SCI-Expanded, Scopus, TRDizin)

17. CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: a multicenter study

DEMİRCİ U., KIRKIZLAR H. O., ÜMİT E. G., GÜRSOY V., PINAR İ. E., ÖZKALEMKAŞ F., et al.

Journal of Hematopathology , cilt.15, sa.4, ss.203-213, 2022 (SCI-Expanded, Scopus)

18. The prognostic significance of blood counts in patients with hodgkin lymphoma

Aras M., ALBAYRAK M., Yildiz A., Maral S., AFACAN ÖZTÜRK H. B., Tiglioglu P., et al.

Nigerian Journal of Clinical Practice , cilt.25, sa.8, ss.1332-1337, 2022 (SCI-Expanded, Scopus)

19. Analysis of factors associated with the development of myelofibrosis in polycythemia vera and essential thrombocythemia patients: a single-center experience

Tığlıoğlu P., ALBAYRAK M., Yıldız A., Tığlıoğlu M., Sağlam B., Aras M. R., et al.

Journal of Hematopathology , cilt.15, sa.2, ss.83-93, 2022 (SCI-Expanded, Scopus)

20. Association of Thrombin-Activatable Fibrinolysis Inhibitor with Acute Pulmonary Embolism

Ylldlz A., Katar D., Soydaś A. Ö., ALBAYRAK M.

Hamostaseologie , cilt.42, sa.3, ss.180-184, 2022 (SCI-Expanded, Scopus)

21. Leukocytoclastic vasculitis due to ruxolitinib treatment: A rare adverse effect

Tığlıoğlu M., Tığlıoğlu P., Yıldız A., Reis Aras M., Sağlam B., AFACAN ÖZTÜRK H. B., et al.

Journal of Clinical Pharmacy and Therapeutics , cilt.47, sa.4, ss.544-547, 2022 (SCI-Expanded, Scopus)

22. Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment

Yılmaz F., ALBAYRAK M., Tığlıoğlu P., Tığlıoğlu M., Sağlam B., Reis Aras M., et al.

Journal of Oncology Pharmacy Practice , cilt.28, sa.3, ss.725-728, 2022 (SCI-Expanded, Scopus)

23. The outcome of COVID-19 in patients with hematological malignancy

Tığlıoğlu P., ALBAYRAK M., Tığlıoğlu M., AFACAN ÖZTÜRK H. B., Aras M. R., Sağlam B., et al.

Memo - Magazine of European Medical Oncology , cilt.15, sa.1, ss.83-89, 2022 (ESCI, Scopus)

24. The clinicopathological features and survival of Castleman disease: A multicenter Turkish study

Yildiz J., Bagci M., Sayin S., Kaya A., YILMAZ F. H., EKİNCİ O., et al.

European Review for Medical and Pharmacological Sciences , cilt.26, sa.4, ss.1131-1137, 2022 (SCI-Expanded, Scopus)

25. Therapeutic Plasma Exchange in Neurological Disorders: A 9-year Experience

Aras M. R., Panpalli Ates M., ALBAYRAK M., AFACAN ÖZTÜRK H. B., Yildiz A., Yilmaz F., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.32, sa.4, ss.202-208, 2022 (SCI-Expanded, Scopus, TRDizin)

26. Hypercalcemia associated with the interaction between all trans retinoic acid and posaconazole in an acute promyelocytic leukemia case

AFACAN ÖZTÜRK H. B., ALBAYRAK M., Maral S., Reis Aras M., Yilmaz F., Akyol P., et al.

Journal of Oncology Pharmacy Practice , cilt.27, sa.8, ss.2027-2029, 2021 (SCI-Expanded, Scopus)

27. Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey

Kalpakci Y., Hacibekiroglu T., Darcin T., AkgunCagliyan G., KIZIL ÇAKAR M., Hacioglu S. K., et al.

Transfusion and Apheresis Science , cilt.60, sa.5, 2021 (SCI-Expanded, Scopus)

28. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study

Akay O. M., Ozbalak M., Pehlivan M., Yildiz B., UZAY A., YİĞENOĞLU T. N., et al.

Hematological Oncology , cilt.39, sa.4, ss.498-505, 2021 (SCI-Expanded, Scopus)

29. Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey

DAL M. S., Merdin A., ERKURT M. A., Ekinci Ö., ALBAYRAK M., Hacıoglu S. K., et al.

Journal of B.U.ON. , cilt.26, sa.4, ss.1536-1539, 2021 (SCI-Expanded, Scopus)

30. Mean platelet volume is a predictive and prognostic marker for patients with acute myeloid leukemia: a two-center retrospective analysis

Tığlıoğlu M., ALBAYRAK M., Doğan S., Yılmaz F., Akyol P., Sağlam B., et al.

Leukemia and Lymphoma , cilt.62, sa.11, ss.2755-2761, 2021 (SCI-Expanded, Scopus)

31. A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis

MALKAN Ü. Y., ALBAYRAK M., Yildiz A., Maral S., AFACAN ÖZTÜRK H. B., Comert P.

Journal of Oncology Pharmacy Practice , cilt.27, sa.1, ss.250-252, 2021 (SCI-Expanded, Scopus)

32. Analysis of Demographic and Clinical Characteristics of Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Patients

Akyol P., Yıldız A., ALBAYRAK M., AFACAN ÖZTÜRK H. B., Maral S., Aras M. R., et al.

Gulhane Medical Journal , cilt.63, sa.2, ss.117-122, 2021 (Scopus, TRDizin)

33. Thrombocytopenia due to rivaroxaban: A rare adverse effect

Tığlıoğlu M., Akyol P., Sağlam B., Aras M. R., AFACAN ÖZTÜRK H. B., Yıldız A., et al.

Transfusion and Apheresis Science , cilt.59, sa.6, 2020 (SCI-Expanded, Scopus)

34. A Signet Ring Cell Carcinoma Presented as Refractory Acquired Thrombotic Thrombocytopenic Purpura

MALKAN Ü. Y., ALBAYRAK M., AFACAN ÖZTÜRK H. B., Reis Aras M., Saglam B., Dogan K.

Case Reports in Oncology , cilt.13, sa.3, ss.1368-1372, 2020 (ESCI, Scopus)

35. Primary Splenic Diffuse Large B Cell Lymphoma. Case Report and Literature Review

AFACAN ÖZTÜRK H. B., ALBAYRAK M., Pala Ç., Yıldız A., Maral S., Şahin O., et al.

SN Comprehensive Clinical Medicine , cilt.2, sa.11, ss.2448-2451, 2020 (Scopus)

36. Prognostic Value of Baseline Serum Lactate Dehydrogenase Level in Patients With Hairy Cell Leukemia

Maral S., ALBAYRAK M., DAĞDAŞ S., Yıldız A., Yıldırım R., Oz M., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.20, sa.9, 2020 (SCI-Expanded, Scopus)

37. Ibrutinib-induced polyneuropathy: A case report

Cömert P., ALBAYRAK M., Yıldız A., Şahin O., AFACAN ÖZTÜRK H. B., Reis Aras M.

Journal of Oncology Pharmacy Practice , cilt.26, sa.6, ss.1501-1504, 2020 (SCI-Expanded, Scopus)

38. Q fever as a rare cause of hemophagocytic lymphohistiocytosis: Case report

Sağlam B., ALBAYRAK M., Acar A., Yıldız A., Maral S., Tığlıoğlu M., et al.

Transfusion and Apheresis Science , cilt.59, sa.4, 2020 (SCI-Expanded, Scopus)

39. Diffuse large B cell lymphoma progression with skin involvement: A case report

Akyol P., ALBAYRAK M., Maral S., CANPOLAT F. E., AFACAN ÖZTÜRK H. B., Sağlam B., et al.

Journal of Tissue Viability , cilt.29, sa.3, ss.216-217, 2020 (SCI-Expanded, SSCI, Scopus)

40. A Rare Entity in Chronic Myelocytic Leukemia: Coexistence of BCR ABL1 Translocation and JAK2 V617F Mutation. Case Report

Sağlam B., ALBAYRAK M., Yıldız A., Akyol P., Öztürk Ç. P., Maral S., et al.

SN Comprehensive Clinical Medicine , cilt.2, sa.4, ss.478-480, 2020 (Scopus)

41. The incidence and risk factors of thrombosis and the need for thromboprophylaxis in lymphoma and leukemia patients: A 9-year single-center experience

Yıldız A., ALBAYRAK M., Pala Ç., AFACAN ÖZTÜRK H. B., Maral S., Şahin O., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.2, ss.386-396, 2020 (SCI-Expanded, Scopus)

42. A case of systemic amyloidosis associated with multiple myeloma diagnosed with skin findings Deri Bulgularıyla Tanı Konulan Multipl Miyelomla İlişkili Bir Sistemik Amiloidoz Olgusu

Erdem B., GÖNÜL M., Ateş D., GÖKÖZ Ö., ALBAYRAK M., Akdağ İ.

Turkiye Klinikleri Dermatoloji , cilt.30, sa.1, ss.30-34, 2020 (Scopus, TRDizin)

43. Absolute lymphocyte count is a predictor of outcome after splenectomy for immune thrombocytopenia

Yildiz A., ALBAYRAK M., Pala Ç., Şahin O., Kuş A., Maral S., et al.

Gulhane Medical Journal , cilt.62, ss.103-108, 2020 (Scopus, TRDizin)

44. Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma

Cömert P., Yıldız A., YILDIRIM M., AFACAN ÖZTÜRK H. B., Pala Ç., ALBAYRAK M., et al.

Indian Journal of Hematology and Blood Transfusion , cilt.36, sa.1, ss.78-83, 2020 (SCI-Expanded, Scopus)

45. A first time report on the coocurrence of sarcoidosis and ALK(−) CD30(+) anaplastic large cell lymphoma that is highly responsive to brentuximab vedotin treatment

AFACAN ÖZTÜRK H. B., ALBAYRAK M., Pala Öztürk Ç., Yıldız A., Maral S., ÖNDER E.

Journal of Oncology Pharmacy Practice , cilt.25, sa.7, ss.1801-1805, 2019 (SCI-Expanded, Scopus)

46. Is antimicrobial prophylaxis necessary for lymphoma patients? A single centre, real-life experience

Yıldız A., AFACAN ÖZTÜRK H. B., ALBAYRAK M., Pala Ç., Şahin O., Maral S., et al.

Journal of Oncology Pharmacy Practice , cilt.25, sa.6, ss.1381-1387, 2019 (SCI-Expanded, Scopus)

47. An acute transverse myelitis attack after autologous stem cell transplantation: A rare case

Cömert P., ALBAYRAK M., Yıldız A., Şahin O., Öztürk Ç. P., Maral S., et al.

Transfusion and Apheresis Science , cilt.58, sa.3, ss.341-343, 2019 (SCI-Expanded, Scopus)

48. The Turkish experience with therapeutic plasma exchange: A national survey

KORKMAZ S., Solmaz Medeni S., Demirkan F., BEŞIŞIK S., Altay Dadin S., Akgun Cagliyan G., et al.

Transfusion and Apheresis Science , cilt.58, sa.3, ss.287-292, 2019 (SCI-Expanded, Scopus)

49. Refractory Thrombotic Thrombocytopenic Purpura in a patient with Kaposi sarcoma

Sahin O., ALBAYRAK M., Yıldız A., Pala Ç., Aktas L., Maral S., et al.

Transfusion and Apheresis Science , cilt.58, sa.2, ss.187-189, 2019 (SCI-Expanded, Scopus)

50. The efficacy of double filtration plasmapheresis in the treatment of homozygous familial hypercholesterolemia: A single-center experience

ALBAYRAK M., Yıldız A., Ateş N., Pala Ç.

Transfusion and Apheresis Science , cilt.58, sa.1, ss.61-64, 2019 (SCI-Expanded, Scopus)

51. CD25 expression is associated with autoimmunity in patients with CLL KLL’li hastalarda CD25 ekspresyonu otoimmünite ile ilişkilidir

AFACAN ÖZTÜRK H. B., Yildiz A., ALBAYRAK M., Pala C., Maral S., Falay M.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.29, sa.3, ss.123-129, 2019 (SCI-Expanded, Scopus, TRDizin)

52. Infections in patients with lymphoma: An analysis of incidence, relationship and risk factors

Yıldız A., ALBAYRAK M., Pala Ç., Şahin O., AFACAN ÖZTÜRK H. B., Güneş G., et al.

Journal of Infection in Developing Countries , cilt.12, sa.9, ss.741-747, 2018 (SCI-Expanded, Scopus)

53. Rare aggressive natural killer cell leukemia presented with leukopenia and disseminated intravascular coagulation—a diagnostic challenge

Yıldız A., Şahin O., Öztürk Ç. P., AFACAN ÖZTÜRK H. B., Maral S., ALBAYRAK M.

Journal of Hematopathology , cilt.11, sa.1, ss.5-7, 2018 (SCI-Expanded, Scopus)

54. Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)

Tekgündüz E., Demirkan F., Vural F., GÖKER H., Özdoğu H., KİKİ İ., et al.

Transfusion and Apheresis Science , cilt.56, sa.6, ss.804-808, 2017 (SCI-Expanded, Scopus)

55. Clinical significance of CD87 expression in acute myeloblastic leukemia Akut miyeloblastik lösemide CD87 ekspresyonunun klinik önemi

CERAN F., Ozet G., DAĞDAŞ S., Falay M., ALBAYRAK M., Yokus O., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.26, sa.1, ss.47-53, 2016 (SCI-Expanded, Scopus, TRDizin)

56. Conventional cytogenetics and fish [del13q, del17p, t(11;14), t(4;14)] findings and their relationship with other risk factors in multiple myeloma Multipl myelomda konvansiyonel sitogenetik ve fish [del13q, del17p, t(11;14), t(4;14)] bulgulari ve diǧer risk faktörleri ile Iliflkisi

Balcik O. S., ALBAYRAK M., DAĞDAŞ S., Helvaci N., Yokus O., CERAN F., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.21, sa.4, ss.203-209, 2011 (SCI-Expanded, Scopus, TRDizin)

57. Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma

Balcik O. S., ALBAYRAK M., Uyar M. E., DAĞDAŞ S., Yokus O., CERAN F., et al.

Blood Coagulation and Fibrinolysis , cilt.22, sa.4, ss.260-263, 2011 (SCI-Expanded, Scopus)

58. Assessment of plasma endostatin levels in patients with acute myeloblastic and lymphoblastic leukemia Akut myeloblastik ve lenfoblastik lösemili hastalarda plazma endostatin düzeylerinin deǧerlendirilmesi

DAĞDAŞ S., Ozet G., Yilmaz M., ALBAYRAK M., CERAN F.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.21, sa.4, ss.210-216, 2011 (SCI-Expanded, Scopus, TRDizin)

59. A rare extramedullar involvement in myeloma: Lung parenchyma and association with unfavorable chromosomal abnormalities Miyelom'da nadir bir ekstramedüller tutulum: Akciǧer parankimi ve olumsuz kromozomal anormalliklerle ilişkisi

Balçik Ö. Ş., ALBAYRAK M., DAĞDAŞ S., CERAN F., Özet G., DEMİRAĞ F., et al.

Turkish Journal of Hematology , cilt.27, sa.2, ss.109-112, 2010 (Scopus, TRDizin)

60. Evaluation of risk factors for thrombophilia in patients with cerebral venous thrombosis Serebral venöz tromboz geçiren hastaların trombofilik risk faktörleri açisından deǧerlendirilmesi

Yokşu O., Balçik Ö. Ş., ALBAYRAK M., CERAN F., DAĞDAŞ S., Yilmaz M., et al.

Turkish Journal of Hematology , cilt.27, sa.3, ss.162-167, 2010 (Scopus, TRDizin)

61. Risk factors for thrombophilia in young adults presenting with thrombosis

Yokus O., ALBAYRAK M., Balcik O. S., CERAN F., DAĞDAŞ S., Yilmaz M., et al.

International Journal of Hematology , cilt.90, sa.5, ss.583-590, 2009 (SCI-Expanded, Scopus)

62. A case of multicentric HHV-8 positive Castleman's disease presenting with marked lymphocytosis

DAĞDAŞ S., ALBAYRAK M., Balçik Ö. Ş., Özet G., CERAN F., Erekul S.

Turkish Journal of Cancer , cilt.39, sa.3, ss.110-114, 2009 (Scopus)

63. Development of multiple myeloma in the course of chronic lymphocytic leukemia: Case report Kronik lenfositik lösemi seyrinde multipl miyelom gelişimi: Olgu sunumu

Balçik Ö. Ş., DAĞDAŞ S., ALBAYRAK M., Efe C., Yokuş O., CERAN F., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.18, sa.4, ss.238-241, 2008 (Scopus, TRDizin)

64. The effect of regimes of harvesting autologous peripheric stem cell on the number of CD34(+) cell: Experience at a single center Otolog periferik kök hücre toplama rejimlerinin CD34(+) hücre sayisi üzerine etkisi: Tek merkez deneyimi

Şahin Balçik Ö., DAĞDAŞ S., Keser Güler S., Özet G., Oymak A., Çelik Z., et al.

Turkiye Klinikleri Journal of Medical Sciences , cilt.28, sa.5, ss.640-647, 2008 (Scopus)

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Tez Danışmanlığı

Açık Erişim